A revolutionary treatment for Alzheimer's disease, Lecanemab, is now available at IU Health Arnett in Lafayette, Indiana. This marks a significant advancement in the fight against Alzheimer's, as Lecanemab is the first fully FDA-approved treatment in the United States that targets the disease itself rather than just alleviating symptoms.
Hongkui Jing, a neurologist at IU Health Arnett, emphasizes that while there is no cure for Alzheimer's, Lecanemab offers patients the chance to maintain their independence and cognitive functions longer, providing more quality time before symptoms worsen. Patients eligible for Lecanemab must undergo rigorous testing to determine their stage of Alzheimer's, with the treatment being most effective for those in the mild to early moderate range of dementia.
Administered through biweekly intravenous infusions, Lecanemab's introduction in Lafayette is a game-changer for local patients who previously had to travel to Indianapolis for treatment. Stephanie Veach, a registered nurse at IU Health Arnett, highlights the convenience and emotional relief this brings to patients and their families, especially for those with a family history of Alzheimer's.
Medicare typically covers about 80% of the treatment costs, with private insurance often covering the remainder. Although Lecanemab is not a permanent solution, it represents a significant step forward in Alzheimer's care, offering patients and their loved ones more time together.
IU Health Arnett's commitment to providing this level of care locally underscores the importance of building trust and personal connections with patients, ensuring they receive the best possible support close to home. The infusion centers at IU Health White Memorial and IU Health Arnett Frankfort are also set to begin administering Lecanemab in the coming months, further expanding access to this life-changing treatment.
